Immunome (IMNM) to Post Quarterly Earnings on Wednesday

Immunome (NASDAQ:IMNM) is anticipated to release its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Immunome to announce earnings of ($0.5138) per share and revenue of $0.1670 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Immunome Price Performance

NASDAQ:IMNM opened at $22.76 on Monday. The firm has a market capitalization of $2.58 billion, a P/E ratio of -9.56 and a beta of 2.07. The business has a 50 day simple moving average of $21.20 and a 200 day simple moving average of $22.05. Immunome has a 12-month low of $8.66 and a 12-month high of $27.65.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Citigroup reissued a “buy” rating on shares of Immunome in a report on Thursday, July 9th. HC Wainwright reissued a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Truist Financial raised their price target on shares of Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Barclays started coverage on Immunome in a research report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price objective for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. Thirteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Immunome has an average rating of “Moderate Buy” and an average price target of $33.17.

Insider Buying and Selling at Immunome

In other news, CFO Max Rosett sold 60,000 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $18.23, for a total value of $1,093,800.00. Following the sale, the chief financial officer owned 54,037 shares of the company’s stock, valued at approximately $985,094.51. The trade was a 52.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 101,050 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $21.12, for a total value of $2,134,176.00. Following the completion of the sale, the director owned 308,504 shares of the company’s stock, valued at approximately $6,515,604.48. This trade represents a 24.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 472,142 shares of company stock valued at $10,262,648. 7.21% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Immunome

Several hedge funds and other institutional investors have recently bought and sold shares of IMNM. BNP Paribas Financial Markets boosted its position in shares of Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after purchasing an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after purchasing an additional 3,802 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in Immunome during the third quarter worth approximately $76,000. Velan Capital Investment Management LP acquired a new position in Immunome in the third quarter worth approximately $117,000. Finally, Quarry LP bought a new position in shares of Immunome in the third quarter valued at $117,000. 44.58% of the stock is currently owned by institutional investors.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.